From investor to owner: Sanofi buys Vigil Neuroscience for $470m - BioXconomy

Retrieved on: 2025-05-23 13:36:16

Tags for this article:

Click the tags to see associated articles and topics

From investor to owner: Sanofi buys Vigil Neuroscience for $470m - BioXconomy. View article details on hiswai:

Summary

The article describes Sanofi's acquisition of biotech firm Vigil for $470 million to enhance its neurology portfolio, adding the TREM2 agonist VG-3927. This aligns with Sanofi's strategic focus, impacting the CAC 40 market and bolstering R&D in neurodegenerative diseases.

Article found on: www.bioxconomy.com

View Original Article